Obesity is a strong risk factor for multiple types of cancer. The mechanisms underlying this association are multiple and include increased systemic inflammation, increased alterations in the systemic hormonal milieu, and direct paracrine tumor-promoting effects of adipose tissue, adipose tissue stem cells, and mature adipocytes. These complex mechanisms generate a carcinogenic milieu in multiple tissues in obesity.


Obesity Risk factor Cancer Systemic inflammation Systemic hormonal milieu Adipose tissue Adipocytes 


  1. 1.
    Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348(17):1625–38.PubMedCrossRefGoogle Scholar
  2. 2.
    Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371(9612):569–78.PubMedCrossRefGoogle Scholar
  3. 3.
    Leung CC, Lam TH, Yew WW, Chan WM, Law WS, Tam CM. Lower lung cancer mortality in obesity. Int J Epidemiol. 2011;40:174–82.PubMedCrossRefGoogle Scholar
  4. 4.
    Giovannucci E, Rimm EB, Liu Y, et al. Body mass index and risk of prostate cancer in U.S. health professionals. J Natl Cancer Inst. 2003;95:1240–4.PubMedCrossRefGoogle Scholar
  5. 5.
    Engeland A, Tretli S, Bjorge T. Height, body mass index, and prostate cancer: a follow-up of 950,000 Norwegian men. Br J Cancer. 2003;89:1237–42.PubMedPubMedCentralCrossRefGoogle Scholar
  6. 6.
    MacInnis RJ, English DR. Body size and composition and prostate cancer risk: systematic review and meta-regression analysis. Cancer Causes Control. 2006;17(8):989–1003.PubMedCrossRefGoogle Scholar
  7. 7.
    Pfeiler G, Königsberg R, Hadji P, Fitzal F, Maroske M, Dressel-Ban G, Zellinger J, Exner R, Seifert M, Singer C, Gnant M, Dubsky P. Impact of body mass index on estradiol depletion by aromatase inhibitors in postmenopausal women with early breast cancer. Br J Cancer. 2013;109(6):1522–7.PubMedPubMedCentralCrossRefGoogle Scholar
  8. 8.
    Choi Y, Park B, Jeong BC, et al. Body mass index and survival in patients with renal cell carcinoma: a clinical-based cohort and meta-analysis. Int J Cancer. 2013;132(3):625–34.PubMedCrossRefGoogle Scholar
  9. 9.
    Wang J, Myles B, Wei C, Chang JY, Hofstetter WL, Ajani JA, Swisher SG, Cox JD, Komaki R, Liao Z, Lin SH. Obesity and outcomes in patients treated with chemoradiotherapy for esophageal carcinoma. Dis Esophagus. 2014;27(2):168–75.PubMedPubMedCentralCrossRefGoogle Scholar
  10. 10.
    Renehan AG. The “obesity paradox” and survival after colorectal cancer: true or false? Cancer Causes Control. 2014;25(10):1419–22.PubMedCrossRefGoogle Scholar
  11. 11.
    Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science. 1993;259(5091):87–91.PubMedCrossRefGoogle Scholar
  12. 12.
    Lind MH, Rozell B, Wallin RP, van Hogerlinden M, Ljunggren HG, Toftgard R, et al. Tumor necrosis factor receptor 1-mediated signaling is required for skin cancer development induced by NF-kappaB inhibition. Proc Natl Acad Sci U S A. 2004;101(14):4972–7.PubMedPubMedCentralCrossRefGoogle Scholar
  13. 13.
    Kitakata H, Nemoto-Sasaki Y, Takahashi Y, Kondo T, Mai M, Mukaida N. Essential roles of tumor necrosis factor receptor p55 in liver metastasis of intrasplenic administration of colon 26 cells. Cancer Res. 2002;62(22):6682–7.PubMedGoogle Scholar
  14. 14.
    Camp NJ, Slattery ML. Classification tree analysis: a statistical tool to investigate risk factor interactions with an example for colon cancer (United States). Cancer Causes Control. 2002;13:813–23.PubMedCrossRefGoogle Scholar
  15. 15.
    Savage SA, Abnet CC, Mark SD, Qiao YL, Dong ZW, Dawsey SM, et al. Variants of the IL8 and IL8RB genes and risk for gastric cardia adenocarcinoma and esophageal squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev. 2004;13(12):2251–7.PubMedGoogle Scholar
  16. 16.
    Cheng H, Wang L, Mollica M, Re AT, Wu S, Zuo L. Nitric oxide in cancer metastasis. Cancer Lett. 2014. pii: S0304-3835(14)00351-6. doi: 10.1016/j.canlet.2014.07.014. [Epub ahead of print].
  17. 17.
    Biswas DK, Shi Q, Baily S, Strickland I, Ghosh S, Pardee AB, et al. NF-kappa B activation in human breast cancer specimens and its role in cell proliferation and apoptosis. Proc Natl Acad Sci U S A. 2004;101(27):10137–42.PubMedPubMedCentralCrossRefGoogle Scholar
  18. 18.
    Duffey DC, Chen Z, Dong G, Ondrey FG, Wolf JS, Brown K, et al. Expression of a dominant-negative mutant inhibitor kappa B alpha of nuclear factor-kappaB in human head and neck squamous cell carcinoma inhibits survival, proinflammatory cytokine expression, and tumor growth in vivo. Cancer Res. 1999;59(14):3468–74.PubMedGoogle Scholar
  19. 19.
    Saijo Y, Tanaka M, Miki M, et al. Proinflammatory cytokine IL-1 β promotes tumor growth of Lewis lung carcinoma by induction of angiogenic factors: in vivo analysis of tumor-stromal interaction. J Immunol. 2002;169:469–75.PubMedCrossRefGoogle Scholar
  20. 20.
    Voronov E, Shouval DS, Krelin Y, et al. IL-1 is required for tumor invasiveness and angiogenesis. Proc Natl Acad Sci U S A. 2003;100:2645–50.PubMedPubMedCentralCrossRefGoogle Scholar
  21. 21.
    Williamson RT. On the treatment of glycosuria and diabetes mellitus with sodium salicylate. Br Med J. 1901;1(2100):760–2.PubMedPubMedCentralCrossRefGoogle Scholar
  22. 22.
    Faghihimani E, Aminorroaya A, Rezvanian H, Adibi P, Ismail-Beigi F, Amini M. Salsalate improves glycemic control in patients with newly diagnosed type 2 diabetes. Acta Diabetol. 2013;50(4):537–43.PubMedCrossRefGoogle Scholar
  23. 23.
    Larsen CM, Faulenbach M, Vaag A, Vølund A, Ehses JA, Seifert B, Mandrup-Poulsen T, Donath MY. Interleukin-1 receptor antagonist in type 2 diabetes mellitus. N Engl J Med. 2007;356:1517–26.PubMedCrossRefGoogle Scholar
  24. 24.
    Ursini F, Naty S, Grembiale RD. Infliximab and insulin resistance. Autoimmun Rev. 2010;9(8):536–9.PubMedCrossRefGoogle Scholar
  25. 25.
    Bertagnolli MM, Eagle CJ, Zauber AG, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med. 2006;355:873–84.PubMedCrossRefGoogle Scholar
  26. 26.
    Arber N, Eagle CJ, Spicak J, et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med. 2006;355:885–95.PubMedCrossRefGoogle Scholar
  27. 27.
    Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer. 2004;4(8):579–91.PubMedCrossRefGoogle Scholar
  28. 28.
    Schoen RE, et al. Increased blood glucose and insulin, body size, and incident colorectal cancer. J Natl Cancer Inst. 1999;91:1147–54.PubMedCrossRefGoogle Scholar
  29. 29.
    Lukanova A, Zeleniuch-Jacquotte A, Lundin E, Micheli A, Arslan AA, Rinaldi S, Muti P, Lenner P, Koenig KL, Biessy C, Krogh V, Riboli E, Shore RE, Stattin P, Berrino F, Hallmans G, Toniolo P, Kaaks R. Prediagnostic levels of C-peptide, IGF-I, IGFBP-1-2 and-3 and risk of endometrial cancer. Int J Cancer. 2004;108:262–8.PubMedCrossRefGoogle Scholar
  30. 30.
    Frasca F, Pandini G, Sciacca L, et al. The role of insulin receptors and IGF-I receptors in cancer and other diseases. Arch Phys Biochem. 2008;114(1):23–37.CrossRefGoogle Scholar
  31. 31.
    Cox ME, Gleave ME, Zakikhani M, et al. Insulin receptor expression by human prostate cancers. Prostate. 2009;69(1):33–40.PubMedCrossRefGoogle Scholar
  32. 32.
    Wu Y, Yakar S, Zhao L, Hennighausen L, LeRoith D. Circulating insulin-like growth factor-I levels regulate colon cancer growth and metastasis. Cancer Res. 2002;62(4):1030–5.PubMedGoogle Scholar
  33. 33.
    Missmer SA, Eliassen AH, Barbieri RL, Hankinson SE. Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women. J Natl Cancer Inst. 2004;96:1856–65.PubMedCrossRefGoogle Scholar
  34. 34.
    Allen NE, Key TJ, Dossus L, Rinaldi S, Cust A, Lukanova A, Peeters PH, Onland-Moret NC, Lahmann PH, Berrino F, Panico S, Larrañaga N, Pera G, Tormo MJ, Sánchez MJ, Ramón Quirós J, Ardanaz E, Tjønneland A, Olsen A, Chang-Claude J, Linseisen J, Schulz M, Boeing H, Lundin E, Palli D, Overvad K, Clavel-Chapelon F, Boutron-Ruault MC, Bingham S, Khaw KT, Bueno-de-Mesquita HB, Trichopoulou A, Trichopoulos D, Naska A, Tumino R, Riboli E, Kaaks R. Endogenous sex hormones and endometrial cancer risk in women in the European Prospective Investigation into Cancer and Nutrition (EPIC). Endocr Relat Cancer. 2008;15(2):485–97.PubMedPubMedCentralCrossRefGoogle Scholar
  35. 35.
    Purohit A, Newman SP, Reed MJ. The role of cytokines in regulating estrogen synthesis: implications for the etiology of breast cancer. Breast Cancer Res. 2002;4:65–9.PubMedPubMedCentralCrossRefGoogle Scholar
  36. 36.
    Pugeat M, Nader N, Hogeveen K, Raverot G, Déchaud H, Grenot C. Sex hormone-binding globulin gene expression in the liver: drugs and the metabolic syndrome. Mol Cell Endocrinol. 2010;316(1):53–9.PubMedCrossRefGoogle Scholar
  37. 37.
    Key TJ, Appleby PN, Reeves GK, Roddam A, Dorgan JF, Longcope C, Stanczyk FZ, Stephenson Jr HE, Falk RT, Miller R, Schatzkin A, Allen DS, Fentiman IS, Key TJ, Wang DY, Dowsett M, Thomas HV, Hankinson SE, Toniolo P, Akhmedkhanov A, Koenig K, Shore RE, Zeleniuch-Jacquotte A, Berrino F, Muti P, Micheli A, Krogh V, Sieri S, Pala V, Venturelli E, Secreto G, Barrett-Connor E, Laughlin GA, Kabuto M, Akiba S, Stevens RG, Neriishi K, Land CE, Cauley JA, Kuller LH, Cummings SR, Helzlsouer KJ, Alberg AJ, Bush TL, Comstock GW, Gordon GB, Miller SR, Longcope C, Endogenous Hormones Breast Cancer Collaborative Group. Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J Natl Cancer Inst. 2003;95(16):1218–26.PubMedCrossRefGoogle Scholar
  38. 38.
    Tchernof A, Nolan A, Sites CK, Ades PA, Poehlman ET. Weight loss reduces C-reactive protein levels in obese postmenopausal women. Circulation. 2002;105:564–9.PubMedCrossRefGoogle Scholar
  39. 39.
    Christou NV, Lieberman M, Sampalis F, Sampalis JS. Bariatric surgery reduces cancer risk in morbidly obese patients. Surg Obes Relat Dis. 2008;4:691–5.PubMedCrossRefGoogle Scholar
  40. 40.
    Ahn J, Schatzkin A, Lacey Jr JA, Albanes D, Ballard-Barbash R, Adams KF, Kipnis V, Mouw T, Hollenbeck AR, Leitzmann MF. Adiposity, adult weight change, and postmenopausal breast cancer risk. Arch Intern Med. 2008;167:2091–100.CrossRefGoogle Scholar
  41. 41.
    Rose DP, Komninou D, Stephenson GD. Obesity, adipocytokines, and insulin resistance in breast cancer. Obes Rev. 2004;5:153–65.PubMedCrossRefGoogle Scholar
  42. 42.
    Maehle BO, Tretli S. Pre-morbid body mass index in breast cancer: reversed effect on survival in hormone receptor negative patients. Breast Cancer Res Treat. 1996;41:123–30.PubMedCrossRefGoogle Scholar
  43. 43.
    Dallal CM, Brinton LA, Bauer DC, Buist DS, Cauley JA, Hue TF, Lacroix A, Tice JA, Chia VM, Falk R, Pfeiffer R, Pollak M, Veenstra TD, Xu X, Lacey Jr JV, B ~ FIT Research Group. Obesity-related hormones and endometrial cancer among postmenopausal women: a nested case-control study within the B ~ FIT cohort. Endocr Relat Cancer. 2013;20(1):151–60.PubMedPubMedCentralCrossRefGoogle Scholar
  44. 44.
    Tworoger SS, Eliassen AH, Kelesidis T, et al. Plasma adiponectin concentrations and risk of incident breast cancer. J Clin Endo Metab. 2007;92(4):1510–6.CrossRefGoogle Scholar
  45. 45.
    Cust AE, Kaaks R, Friedenreich C, et al. Plasma adiponectin levels and endometrial cancer risk in pre- and post-menopausal women. J Clin Endo Met. 2007;92(1):255–63.CrossRefGoogle Scholar
  46. 46.
    Wei EK, Giovannucci E, Fuchs CS, Willett WC, Mantzoros CS. Low plasma adiponectin levels and risk of colorectal cancer in men: a prospective study. J Natl Cancer Inst. 2005;97(22):1688–94.PubMedCrossRefGoogle Scholar
  47. 47.
    Ribatti D, Belloni AS, Nico B, Di Comite M, Crivellato E, Vacca A. Leptin–leptin receptor are involved in angiogenesis in human hepatocellular carcinoma. Peptides. 2008;29:1596–602.PubMedCrossRefGoogle Scholar
  48. 48.
    Gonzalez RR, Leavis PC. A peptide derived from the human leptin molecule is a potent inhibitor of the leptin receptor function in rabbit endometrial cells. Endocrine. 2003;21(2):185.PubMedCrossRefGoogle Scholar
  49. 49.
    Surmacz E. Leptin and adiponectin: emerging therapeutic targets in breast cancer. J Mammary Gland Biol Neoplasia. 2013;18(3-4):321–32.PubMedCrossRefGoogle Scholar
  50. 50.
    Mathur A, Zyromski NJ, Pitt HA, Al-Azzawi H, Walker JJ, Saxena R, Lillemoe KD. Pancreatic steatosis promotes dissemination and lethality of pancreatic cancer. J Am Coll Surg. 2009;208(5):989–94.PubMedCrossRefGoogle Scholar
  51. 51.
    Yamaguchi J, et al. Prognostic impact of marginal adipose tissue invasion in ductal carcinoma of the breast. Am J Clin Pathol. 2008;130:382–8.PubMedCrossRefGoogle Scholar
  52. 52.
    Rio MC. The role of cancer-associated adipocytes (CAA) in the dynamic interaction between the tumor and the host. In: Mueller MM, Fusenig NE, editors. Tumor-associated fibroblasts and their matrix, vol. 4. Netherlands: Springer; 2011. p. 111–23.CrossRefGoogle Scholar
  53. 53.
    Manabe Y, et al. Mature adipocytes, but not preadipocytes, promote the growth of breast carcinoma cells in collagen gel matrix culture through cancer-stromal cell interactions. J Pathol. 2003;201(2):221–8.PubMedCrossRefGoogle Scholar
  54. 54.
    Amemori S, et al. Adipocytes and preadipocytes promote the proliferation of colon cancer cells in vitro. Am J Physiol Gastro Liver Physiol. 2007;292(3):G923–9.CrossRefGoogle Scholar
  55. 55.
    White PB, True EM, Ziegler KM, Wang SS, Swartz-Basile DA, Pitt HA, Zyromski NJ. Insulin, leptin, and tumoral adipocytes promote murine pancreatic cancer growth. J Gastrointest Surg. 2010;12:1888–93.CrossRefGoogle Scholar
  56. 56.
    Tokuda Y, Satoh Y, Fujiyama C, Toda S, Sugihara H, Masaki Z. Prostate cancer cell growth is modulated by adipocyte-cancer cell interaction. BJU Int. 2003;91(7):716–20.PubMedCrossRefGoogle Scholar
  57. 57.
    Zhang Y, Daquinag A, Traktuev DO, Amaya-Manzanares F, Simmons PJ, March KL, Pasqualini R, Arap W, Kolonin MG. White adipose tissue cells are recruited by experimental tumors and promote cancer progression in mouse models. Cancer Res. 2009;69(12):5259–66.PubMedCrossRefGoogle Scholar
  58. 58.
    Nieman KM, Kenny HA, Penicka CV, Ladanyi A, Buell-Gutbrod R, Zillhardt MR, Romero IL, Carey MS, et al. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med. 2011;17(11):1498–503.PubMedPubMedCentralCrossRefGoogle Scholar
  59. 59.
    Bochet L, Lehuédé C, Dauvillier S, Wang YY, Dirat B, Laurent V, Dray C, Guiet R, et al. Adipocyte-derived fibroblasts promote tumor progression and contribute to the desmoplastic reaction in breast cancer. Cancer Res. 2013;73(18):5657–68.PubMedCrossRefGoogle Scholar
  60. 60.
    Ehsanipour EA, Sheng X, Behan JW, Wang X, Butturini A, Avramis VI, Mittelman SD. Adipocytes cause leukemia cell resistance to L-asparaginase via release of glutamine. Cancer Res. 2013;73(10):2998–3006.PubMedPubMedCentralCrossRefGoogle Scholar
  61. 61.
    Sheng H, Li P, Chen X, Liu B, Zhu Z, Cao W. Omega-3 PUFAs induce apoptosis of gastric cancer cells via ADORA1. Front Biosci (Landmark Ed). 2014;19:854–61.CrossRefGoogle Scholar
  62. 62.
    Xu Y, Qian SY. Anti-cancer activities of ω-6 polyunsaturated fatty acids. Biomed J. 2014;37(3):112–9.PubMedPubMedCentralGoogle Scholar
  63. 63.
    Zheng H, Tang H, Liu M, He M, Lai P, Dong H, Lin J, Jia C, Zhong M, Dai Y, Bai X, Wang L. Inhibition of endometrial cancer by n-3 polyunsaturated fatty acids in preclinical models. Cancer Prev Res (Phila). 2014;7(8):824–34.CrossRefGoogle Scholar
  64. 64.
    Takino J, Yamagishi S, Takeuchi M. Cancer malignancy is enhanced by glyceraldehyde-derived advanced glycation end-products. J Oncol. 2010;2010:739852.PubMedPubMedCentralCrossRefGoogle Scholar
  65. 65.
    Ley RE. Obesity and the human microbiome. Curr Opin Gastroenterol. 2010;26(1):5–11.PubMedCrossRefGoogle Scholar
  66. 66.
    Thakkar B, Aronis KN, Vamvini MT, Shields K, Mantzoros CS. Metformin and sulfonylureas in relation to cancer risk in type II diabetes patients: a meta-analysis using primary data of published studies. Metabolism. 2013;62(7):922–34.PubMedCrossRefGoogle Scholar
  67. 67.
    Sjostrom L, Narbro K, Sjostrom CD, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med. 2007;357:741–52.PubMedCrossRefGoogle Scholar
  68. 68.
    Birks S, Peeters A, Backholer K, O’Brien P, Brown W. A systematic review of the impact of weight loss on cancer incidence and mortality. Obes Rev. 2012;13(10):868–91.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  1. 1.Department of SurgeryUniversity of MichiganAnn ArborUSA

Personalised recommendations